Senaste uppdateringen :
08/05/2024
Diuretikum   Hydrochlorothiazide  
Oral lösning
Stabilitet av läkemedel Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Hänvisningar Pdf
   Molekylstruktur  

Oral lösning
Hänvisningar   Oral lösning   Hänvisningar : Hydrochlorothiazide  
Typ Publikation
2435 Tidningen Allen LV, Jr, Erickson MA,
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361 Tidningen Santovena A, Hernandez-Paiz Z, Farina J.B.
Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Int J Pharm 2012 ; 423: 360-364.
3399 Affisch Li Y.Y, Postma D.J, Wagenaar H.W.G.
Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children.
EAHP Congress Paris 2013
3910 Tidningen Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O.
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.
EJHP 2016 ; 23: 352-358.
4177 Tidningen Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4198 Tidningen Uriel M, Gomez-Rincon C, Marro D.
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Pharmazie 2018 73;196-201
4256 Tidningen Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A.
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Pharmaceutics 2019 ;11,190:

  Mentions Légales